Summarized by Masters of Longevity from Hevolution Foundation.
Hevolution invested $20 million as lead investor in Aeovian Pharmaceuticals’ $50 million Series A extension to develop selective mTORC1 inhibitors.
Key Takeaways
- Hevolution’s $20 million contribution is part of the $50 million extension.
- Other investors included Apollo Health Ventures, Sofinnova Investments and venBio.
- The funding supports drug development; the announcement does not demonstrate clinical efficacy.
